Subject Experts Committee may soon review Bharat Biotech's intranasal jab as a booster dose

21 Sep 2022 , 08:08 AM

According to a report by ET, the Subject Expert Committee (SEC) of India’s medicines regulator would shortly examine Bharat Biotech’s request for clearance of their intranasal vaccination as a booster dosage.

Following Covishield and Covaxin, the company has conducted clinical trials for the vaccine administered as a heterologous booster dosage and has submitted the data for review to the Drugs Controller General of India (DCGI).

Bharat Biotech, based in Hyderabad, has applied to the Drugs Controller General of India (DCGI) for market authorization approval for their intranasal heterologous booster in the 5—18 age range.

According to the report, “The SEC will shortly take up their application for review and analyze their data as a booster dose.”

Incovacc (intranasal vaccination) was tested in clinical studies as a primary dosage schedule and as a heterologous booster dose for patients who had already received two doses of the two covid vaccines that are often used in India.

The nation’s first intranasal vaccine, Incovacc from Bharat Biotech, was approved earlier this month by the pharma authority for use in the primary immunization of those over the age of 18.

For feedback and suggestions, write to us at [e-mail]